Biogen begins laying off staff as it continues to push its new Alzheimer's drug
The layoffs at Biogen have begun.
In the wake of a controversial approval for its Alzheimer’s drug Aduhelm, Biogen started informing employees Wednesday that their roles were being eliminated, the big biotech said in a statement, as part of a cost-cutting plan implemented in December. Biogen is giving no details on the exact number of layoffs, a practice that falls outside the standard procedure of publicly traded companies even though they are not legally required to do so.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 150,300+ biopharma pros reading Endpoints daily — and it's free.